BNP Paribas Financial Markets Trims Holdings in Kenvue Inc. $KVUE

BNP Paribas Financial Markets decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 48.2% during the fourth quarter, Holdings Channel reports. The fund owned 2,284,970 shares of the company’s stock after selling 2,123,204 shares during the period. BNP Paribas Financial Markets’ holdings in Kenvue were worth $39,416,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Aberdeen Group plc grew its holdings in shares of Kenvue by 84.1% during the 3rd quarter. Aberdeen Group plc now owns 1,411,380 shares of the company’s stock worth $22,914,000 after acquiring an additional 644,930 shares during the period. Oak Thistle LLC purchased a new position in shares of Kenvue during the 4th quarter worth approximately $1,563,000. Eubel Brady & Suttman Asset Management Inc. grew its holdings in shares of Kenvue by 39.7% during the 3rd quarter. Eubel Brady & Suttman Asset Management Inc. now owns 1,371,886 shares of the company’s stock worth $22,266,000 after acquiring an additional 389,704 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Kenvue by 25.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 410,874 shares of the company’s stock worth $7,088,000 after acquiring an additional 84,219 shares during the period. Finally, SG Americas Securities LLC grew its holdings in shares of Kenvue by 3,889.9% during the 4th quarter. SG Americas Securities LLC now owns 3,075,723 shares of the company’s stock worth $53,056,000 after acquiring an additional 2,998,635 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

KVUE has been the topic of a number of research analyst reports. UBS Group reduced their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Tuesday, April 7th. Canaccord Genuity Group upped their price target on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Argus upgraded Kenvue to a “hold” rating in a research note on Friday, March 6th. Barclays cut their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 14th. Finally, Weiss Ratings downgraded Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $19.33.

Insider Transactions at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 1.59% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $16.86 on Thursday. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $32.37 billion, a P/E ratio of 19.84, a PEG ratio of 1.31 and a beta of 0.54. The stock’s 50 day moving average is $17.38 and its 200 day moving average is $17.47. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $22.87.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. The company had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.24 EPS. On average, equities research analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were given a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.9%. Kenvue’s dividend payout ratio is 97.65%.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.